CS Paper Radar

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong, Xingquan Zhu, Yi He

cs.LG cs.CL ·submitted 2026-10-04 22:54 UTC · v1
publishedbenchmarkcode/data

Abstract

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

Comment
Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Closest papers

Nearest neighbours by meaning across the whole index.

MoEDDI: Semantic Mixtures of Experts for Long Tailed Drug Drug Interaction Prediction

cs.LG ·2026-10-31 ·Dinh Tan Nguyen, Hien Quang Kha, Minh-Toan Dinh, Xuan-Huy Nguyen, Phu. D Ho +3 more
similarity 0.70
Abstract

Descriptor-based drug--drug interaction (DDI) models typically apply a single global predictor despite heterogeneous physicochemical evidence and severely long-tailed labels. We introduce \textbf{MoEDDI (Mixture-of-Experts for Drug--Drug Interaction prediction)}, a chemically organized mixture-of-experts that routes overlapping descriptor families using low-dimensional statistics and combines their sparse top-$2$ mixture with a global T-DDI pathway through a residual logit correction. The residual parameterization can exactly preserve a supplied T-DDI checkpoint at initialization, although the evaluated models are trained from scratch. Across complete test partitions with 178, 86, and 92 classes, MoEDDI improves macro-F1 over reproduced seed-2026 T-DDI baselines from 0.8284 to 0.8485, 0.4729 to 0.6536, and 0.1807 to 0.4671. On the 3,780-feature corpus, the lowest-support group (89 classes with fewer than 50 test examples) shows the largest mean classwise gain (+3.30 F1 points). Calibration improves on one corpus but worsens on two. These single-seed results support semantic conditional specialization while motivating matched ablations and distribution-shift evaluation.

0.19

VINCENT: Validated Interaction Network for Cross-drug Explanation of Therapeutics

cs.LG cs.AI ·2026-08-26 ·Fan-Sheng Chuang, Xuchen Li, Yujing Bian, Kaixiong Zhou
similarity 0.69
Abstract · 18 pages, 4 figures

Drug synergy prediction estimates whether two drugs produce a stronger joint effect than expected from their individual activities. For drug combination discovery, a single synergy score is often not enough: researchers also need to know which molecular regions jointly drive the prediction. We study motif-pair synergy explanation, which identifies pairs of chemically coherent regions, one from each drug, that jointly contribute to predicted synergy. Existing interpretable synergy models expose atom- or substructure-level signals, but their explanations are built into the predictor architecture, and none validates cross-drug region scores under repeated perturbations or feeds that evidence back to refine the explanation. A reliable motif-pair explanation should instead be chemically coherent, perturbation-stable, and aligned with predictor behavior. We introduce VINCENT (Validated Interaction Network for Cross-drug Explanation of Therapeutics), a post-training framework for a fixed interaction-aware synergy predictor. VINCENT extracts atom-pair evidence from attention and gradient signals, groups atoms into chemically coherent motifs, and validates candidate motif pairs through repeated local perturbations. The validated evidence is fed back to refine motif assignments, yielding explanations that satisfy these three criteria. On a 25-pair literature-annotated subset, VINCENT achieves a mean motif recall of 0.826 (95% CI: 0.78-0.87), compared with 0.49-0.66 for baselines. Across all 71 test pairs, its validated interaction scores yield a TP/TN separation of 3.36. These results show that closed-loop perturbation validation recovers literature-supported molecular regions more accurately than existing alternatives while producing cross-drug interaction scores that better reflect predictor behavior.

0.16

DPTM-DT: Dual-Pretrained Transformer Multitask Representation Learning for Drug-Target Prediction

cs.LG cs.AI ·2026-08-28 ·Ge Kong
code/data similarity 0.67
Abstract

Drug-target relation prediction supports candidate screening, drug repositioning, and mechanism analysis. Existing models often use incomplete drug or protein representations, model cross-modal interactions shallowly, or train affinity regression and interaction classification separately, although these tasks describe closely related views of the same drug-target pair. This paper presents DPTM-DT, a dual-pretrained Transformer framework for multitask drug-target prediction. DPTM-DT combines GROVER molecular graph embeddings, ESM protein language-model embeddings, and CTD physicochemical descriptors, then exchanges drug-target information through bidirectional cross-modal attention. A shared pair representation is used for continuous affinity regression, high-affinity binary classification, and six-level affinity classification. Experiments on Davis and KIBA cover random 80/20 and DeepDTA-style standard splits. On the random 80/20 split, DPTM-DT achieves MSE/CI values of 0.193/0.917 on Davis and 0.120/0.918 on KIBA. It also reports binary AUPR/MCC values of 0.727/0.654 and 0.798/0.689, and six-class Macro-F1/Top-2 values of 0.800/0.932 and 0.815/0.962 on Davis and KIBA, respectively. Across the reported regression, binary classification, and multiclass classification settings, DPTM-DT achieves the best overall performance among the compared methods. Results under the standard split show the same relative trend. Ablations indicate that dual target representation, gated fusion, and cross-modal attention each contribute to the final performance. Code and supplementary materials are available at: anonymous.4open.science/r/DPCM-DT-74E0.

0.26

Monroe: A Molecular Foundation Model for In-Context Probabilistic Inference

cs.LG q-bio.BMq-bio.QM ·2026-08-19 ·Blazej Banaszewski, Andrew W. Fitzgibbon
publishedcode/data similarity 0.67
Abstract · 40th Conference on Neural Information Processing Systems (NeurIPS 2026)

Bioassay activity prediction is often data-limited because drug-discovery datasets rely on time-consuming and expensive wet-lab experiments for data generation and evaluation. This challenge has inspired recent research into molecular foundation models (MFMs), which aim to encode general-purpose chemical knowledge into molecular representations that generalize well in data-constrained scenarios. This paper presents Monroe, a new MFM with several innovations over the existing state of the art: increased scale allowing pre-training on over 81 million molecules from the PM6 quantum chemistry dataset; improved graph representation of stereochemistry; improved training losses including conformer denoising and embedding decorrelation; improved multi-task learning; and the use of a prior-data-fitted model (TabPFNv3) for downstream in-context prediction. Our evaluations use a principled pairwise comparison framework that measures statistically significant performance differences. Across established Polaris benchmarks, Monroe matches or exceeds existing MFMs, while on activity cliff benchmarks, designed to assess utility for molecular discovery, it achieves significant improvements over prior methods. Finally, ablation and transfer experiments show that PFN-based downstream predictors also substantially improve two leading existing models, MiniMol and CheMeleon, yielding new state-of-the-art variants we call MiniMol_PFN and CheMeleon_PFN, suggesting that our downstream adaptation strategy generalizes beyond Monroe. Source code is at github.com/blazejba/Monroe

0.51

DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing

cs.LG cs.AI ·2026-09-06 ·Zijie Liu, Hongxuan Li, Zhen Tan, Jinhao Duan, Baixiang Huang +3 more
top venuecode/data similarity 0.66
Abstract · EMNLP 2026 Main Conference Code: https://github.com/jesseliu0913/DrugReason

Drug repurposing aims to identify new therapeutic uses for existing compounds and, compared with de novo drug discovery, offers a faster and more cost-effective path to clinical translation. However, the space of candidate drug-disease pairs is enormous and their underlying relationships often depend on complex multi-hop biological mechanisms, making it difficult to reliably predict which pairs represent true therapeutic relationships. Existing approaches tackle this from two directions: knowledge graph-based methods organize curated biomedical evidence into structured relational networks for grounded multi-hop reasoning, while LLM-based methods leverage pretrained knowledge to generate flexible mechanistic rationales. Yet neither is sufficient alone - KGs are confined to observed graph structure while LLMs lack factual grounding and risk hallucination. To address this gap, we propose DrugReason, a multi-view reasoning framework that integrates grounded KG reasoning with LLM-generated mechanistic inference for drug repurposing. DrugReason adaptively routes diverse reasoning paths to specialized experts conditioned on the query context, while a cross-expert distillation objective enables knowledge sharing without sacrificing expert specialization. Experiments on PharmaDB, DDInter, and DrugBank show that DrugReason improves average performance over strong single-view reasoning baselines and achieves competitive or superior results compared with graph-based alternatives, while providing interpretable routing-based predictions.

0.53

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.66
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

Entropy-Guided Reverse-Causal AI to Identify Upstream Bottleneck Genes for Alzheimer's Drug Discovery

cs.CE ·2026-10-06 ·Victor O. K. Li, Jacqueline C. K. Lam, Yang Han, Lawrence Y. L. Cheung
similarity 0.66
Abstract

Identifying upstream regulators that connect several disease processes to therapeutic interventions is a central objective in Alzheimer's disease drug discovery. We propose an entropy-guided reverse-causal framework that makes candidate bottleneck genes the organizing link between disease mechanisms, pathways, molecular targets and drugs. The methodology integrates five stages: an Alzheimer's-specific knowledge graph with language-model assistance and expert review; reverse tracing from drugs to candidate genes; entropy-guided prioritization; forward propagation to drugs and complementary combinations; and staged validation with evidence feedback. The novelty lies in integrating upstream bottleneck identification, entropy-guided prioritization and iterative therapeutic selection within a dynamic, bidirectional discovery architecture. We demonstrate its molecular tracing and gene-prioritization components in a computational feasibility study using DeepDrug2 and MSigDB pathway annotations. Tracing amlodipine, indapamide and atorvastatin through a network of 11,300 molecular and drug nodes identifies 46 routes to nine genes. EGFR is the leading candidate, supported by 26 routes from all three drugs; MME and MAF rank next. These results show how pharmacological starting points can identify shared candidate genes with defined molecular connections. The framework's scientific significance lies in connecting convergent disease mechanisms to systematic intervention selection, with preservation of cognition and independence as the translational objective.

0.10

CellChain: Benchmarking Cross-Scale Evidence Use for Perturbation Reasoning

cs.DB q-bio.GN ·2026-10-12 ·Xue Xia, Yue Wang, Shuizhou Chen, Lang Yu, Hao Wu +4 more
benchmark similarity 0.65
Abstract · 21 pages, 6 figures

Recent advances in foundation models and large-scale cellular perturbation datasets have driven growing interest in using LLMs to predict and reason about cellular responses. Biological reasoning in this setting involves relating molecular mechanisms, cellular responses, and functional outcomes across scales. Evaluating foundation models therefore requires assessing not only whether their predictions are correct, but also how those predictions depend on the biological evidence provided. We introduce CellChain, an experimentally grounded benchmark comprising 590 biological cases and 2,360 matched evidence-condition instances across gene-dependency prediction, cytokine-axis identification, and drug-sensitivity ranking. CellChain links perturbation experiments and external biological resources through a provenance-aware evidence graph spanning molecular, pathway, transcriptional, and phenotypic information. Task-specific conditions vary evidence coverage, composition, or assignment while preserving questions, candidate answers, reference targets, and scoring rules. Across 18 foundation models, the highest accuracies under prespecified target-evidence conditions are 57.5%, 75.5%, and 70.8%, respectively, and broader evidence coverage does not consistently improve accuracy. On the drug-sensitivity benchmark cohort, matched reference histories outperform swapped histories by an average of 13.0 percentage points in cluster-weighted accuracy. Decision-transition analysis separates corrections, newly introduced errors, and wrong-answer switches, revealing substantial answer changes hidden by small net accuracy differences. CellChain provides controlled comparisons for attributing changes in model predictions to prespecified expansions of biological context, including changes in evidence coverage, composition, and biological assignment.

0.19